Can rivaroxaban reduce cardiovascular events in advanced CKD?
The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high cardiovascular risk.
Check out the latest VA and review the next #NephJC.